# High Throughput Screening Core

> **NIH NIH U19** · HACKENSACK UNIVERSITY MEDICAL CENTER · 2022 · $8,363,749

## Abstract

PROJECT SUMMARY
The overall goal of this program is to discover and develop small molecule orally bioavailable drugs to treat
SARS-CoV2 and other viruses with pandemic potential. Our specific role is to provide a central core facility, with
expertise and technologies that use high-throughput screening to identify potent and selective drug-like lead
compounds and further characterize these compounds for concentration-response relationships, affinity,
stoichiometry, off-rates, contributions of entropy and enthalpy of binding of the chosen molecular targets. We will
also support testing in high-throughput phenotypic assays for anti-viral efficacy. We intend to work closely with
the project leaders and medicinal chemists to rapidly gain critical information on the mechanism of action of
various compounds derived from the chemical scaffolds identified in the screens conducted and to support
medicinal chemistry programs in testing improved congeners for potency and selectivity against the primary
targets.

## Key facts

- **NIH application ID:** 10513916
- **Project number:** 1U19AI171401-01
- **Recipient organization:** HACKENSACK UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Joseph FRASER GLICKMAN
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $8,363,749
- **Award type:** 1
- **Project period:** 2022-05-16 → 2026-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10513916

## Citation

> US National Institutes of Health, RePORTER application 10513916, High Throughput Screening Core (1U19AI171401-01). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10513916. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*